BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (Nasdaq:CELG) today announced the publication of peer-reviewed data from a Phase II study of REVLIMID in relapsed or refractory aggressive non-Hodgkin’s lymphoma in the Journal of Clinical Oncology. According to the data, REVLIMID, as an oral monotherapy, demonstrated activity in patients at an advanced stage of the disease who had received a median of four prior treatments and had limited treatment options.
